Key Clinical Points Postmenopausal Osteoporosis Fragility fractures are very common
among postmenopausal women and are associated with increased morbidity, mortality, and …

Context Denosumab discontinuation is characterized by an increase in bone turnover
overriding pretreatment status, a rapid bone loss in the majority and multiple vertebral …

Objective The objective is to formulate clinical practice guidelines for the pharmacological
management of osteoporosis in postmenopausal women. Conclusions Evidence from …

Osteoporosis is called the 'silent disease'because, although it does not give significant
symptoms when it is not complicated, can cause fragility fractures, with serious …

Evidence shows the quality of reporting of randomised controlled trials is not optimal. The
lack of transparent reporting impedes readers from judging the reliability and validity of trial …

Skeletal complications caused by osteoporosis or bone metastases are associated with
considerable pain, increased mortality, and reduced quality of life. Furthermore, such events …

Objective The development of these guidelines is sponsored by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology …

Introduction The optimal duration of osteoporosis treatment is controversial. As opposed to
bisphosphonates, denosumab does not incorporate into bone matrix and bone turnover is …

The fully human monoclonal antibody denosumab was approved for treatment of
osteoporosis in 2010 on the basis of its potent antiresorptive activity, which produces …

Objective To review the comparative effectiveness of osteoporosis treatments, including the
bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in …